Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma

Veterinary and Comparative Oncology

Volumn 13, Issue 3, 2015, Pages 203-217

  Martin, C K ^a   Dirksen, W P ^a   Carlton, M M ^b   Lanigan, L G ^a   Pillai, S P ^a   Werbeck, J L ^a   Simmons, J K ^a   Hildreth, B E ^a   London, C A ^a   Toribio, R E ^a   Rosol, T J ^a  

^a Farm Animal Medicine and Surgery   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Bone invasion; Bone resorption; Feline; Meloxicam; Oral squamous cell carcinoma; Zoledronic acid

Indexed keywords

FELIDAE; MUS;

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMIDAZOLE DERIVATIVE; MELOXICAM; MESSENGER RNA; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANALYSIS OF VARIANCE; ANIMAL; BONE NEOPLASMS; CAT; CAT DISEASES; DISEASE MODEL; HUMAN; MALE; MOUSE; MOUTH NEOPLASMS; NEOPLASMS, SQUAMOUS CELL; NUDE MOUSE; OSTEOLYSIS; PATHOLOGY; PREVENTION AND CONTROL; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE; VETERINARY; XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CAT DISEASES; CATS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASMS, SQUAMOUS CELL; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84939651009     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12037     Document Type: Article

References (57)

1. Dorn CR and Priester WA. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. Journal of the American Veterinary Medical Association 1976; 169: 1202-1206.
2. Morris J and Dobson J. Head and neck. In: Small Animal Oncology. J Morris and J Dobson Eds., Oxford, Alder Press Ltd./Blackwell Science Ltd, 2001: 94-124.
3. Martin CK, Tannehill-Gregg SH, Wolfe TD and Rosol TJ. Bone-invasive oral squamous cell carcinoma in cats: pathology and expression of parathyroid hormone-related protein. Veterinary Pathology 2011; 48: 302-312.
4. Karmali RA, Wustrow T, Thaler HT and Strong EW. Prostaglandins in carcinomas of the head and neck. Cancer Letters 1984; 22: 333-336.
5. Jung TT, Berlinger NT and Juhn SK. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985; 95: 307-312.
6. Tannehill-Gregg S, Kergosien E and Rosol TJ. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. In Vitro Cellular & Developmental Biology. Animal 2001; 37: 676-683.
7. Kukreja SC, Rosol TJ, Wimbiscus SA, Shevrin DH, Grill V, Barengolts EI and Martin TJ. Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. Endocrinology 1990; 127: 305-310.
8. Shibahara T, Nomura T, Cui NH and Noma H. A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery 2005; 34: 789-793.
9. Okamoto M, Hiura K, Ohe G, Ohba Y, Terai K, Oshikawa T, Furuichi S, Nishikawa H, Moriyama K, Yoshida H and Sato M. Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 2000; 89: 1966-1975.
10. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Research 1999; 59: 991-994.
11. Chirgwin JM and Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Critical Reviews in Eukaryotic Gene Expression 2000; 10: 159-178.
12. Werkmeister JR, Blomme EA, Weckmann MT, Grone A, McCauley LK, Wade AB, O'Rourke J, Capen CC and Rosol TJ. Effect of transforming growth factor-beta1 on parathyroid hormone-related protein secretion and mRNA expression by normal human keratinocytes in vitro. Endocrine 1998; 8: 291-299.
13. Rosol TJ. Pathogenesis of bone metastases: role of tumor-related proteins. Journal of Bone and Mineral Research 2000; 15: 844-850.
14. Hiraga T, Myoui A, Choi ME, Yoshikawa H and Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Research 2006; 66: 2067-2073.
15. McCauley LK, Beecher CA, Melton ME, Werkmeister JR, Juppner H, Abou-Samra AB, Segre GV and Rosol TJ. Transforming growth factor-beta1 regulates steady-state PTH/PTHrP receptor mRNA levels and PTHrP binding in ROS 17/2.8 osteosarcoma cells. Molecular and Cellular Endocrinology 1994; 101(1-2): 331-336.
16. Martin CK, Dirksen WP, Shu ST, Werbeck JL, Thudi NK, Yamaguchi M, Wolfe TD, Heller KN and Rosol TJ. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. Oral Oncology 2012; 48: 491-499.
17. Hayes A, Scase T, Miller J, Murphy S, Sparkes A and Adams V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. Journal of Comparative Pathology 2006; 135: 93-99.
18. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research 1998; 58: 362-366.
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
20. Tsujii M, Kawano S and DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 3336-3340.
21. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Research 1998; 58: 1208-1216.
22. Akatsu T, Takahashi N, Debari K, Morita I, Murota S, Nagata N, Takatani O and Suda T. Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3', 5'-monophosphate in mouse bone marrow cell cultures. Journal of Bone and Mineral Research 1989; 4: 29-35.
23. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M and Ringel MD. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001; 11: 339-351.
24. Saito S, Rosol TJ, Saito M, Ngan PW, Shanfeld J and Davidovitch Z. Bone-resorbing activity and prostaglandin E produced by human periodontal ligament cells in vitro. Journal of Bone and Mineral Research 1990; 5: 1013-1018.
25. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG and Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 7829-7834.
26. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H and Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clinical & Experimental Metastasis 2006; 23: 19-31.
27. Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ and Rosol TJ. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 2008; 68: 1116-1125.
28. Wolfe TD, Pillai SP, Hildreth BE 3rd, Lanigan LG, Martin CK, Werbeck JL and Rosol TJ. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clinical & Experimental Metastasis 2011; 28: 377-389.
29. Martin CK, Werbeck JL, Thudi NK, Lanigan LG, Wolfe TD, Toribio RE and Rosol TJ. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. Cancer Research 2010; 70: 8607-8616.
30. Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C and Shibahala T. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clinical Cancer Research 2005; 11: 2713-2719.
31. Roh JL, Sung MW and Kim KH. Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head & Neck 2005; 27: 326-332.
32. Wang Z, Fuentes CF and Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112: 839-843.
33. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS and Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clinical Cancer Research 2005; 11: 2089-2096.
34. Sievers EM, Bart RD, Backhus LM, Lin Y, Starnes M, Castanos R, Starnes VA and Bremner RM. Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect. The Journal of Thoracic and Cardiovascular Surgery 2005; 129: 1242-1249.
35. Smakman N, Schaap N, Snijckers CM, Borel Rinkes IH and Kranenburg O. NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation. Urology 2005; 66: 434-440.
36. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N and Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Research 2006; 26(6B): 4245-4254.
37. Tanaka T, Nishikawa A, Mori Y, Morishita Y and Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Letters 1989; 48: 177-182.
38. Shu ST, Martin CK, Thudi NK, Dirksen WP and Rosol TJ. Osteolytic bone resorption in adult T-cell leukemia/lymphoma. Leukemia & Lymphoma 2010; 51: 702-714.
39. Tannehill-Gregg SH, Levine AL and Rosol TJ. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Veterinary and Comparative Oncology 2006; 4: 84-97.
40. Wu WK, Sung JJ, Lee CW, Yu J and Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Letters 2010; 295: 7-16.
41. Ko SH, Choi GJ, Lee JH, Han YA, Lim SJ and Kim SH. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncology Reports 2008; 19: 425-433.
42. Liu JF, Zhang SW, Jamieson GG, Zhu GJ, Wu TC, Zhu TN, Shan BE and Drew PA. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. International Journal of Cancer 2008; 122: 1639-1644.
43. Naruse T, Nishida Y, Hosono K and Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 2006; 27: 584-592.
44. Jiang X, Li H, Qiao H, Jiang H, Xu R and Sun X. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Science 2009; 100: 2226-2233.
45. Xin B, Yokoyama Y, Shigeto T and Mizunuma H. Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathology and Oncology Research 2007; 13: 365-369.
46. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M and Norer B. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncology 2007; 43: 193-198.
47. Martin-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baro T, Alameda Quitllet F, Yebenes M, Sole F, Garcia-Muret M, Espinet B and Pujol RM. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. British Journal of Dermatology 2010; 163: 1028-1035.
48. Looper JS, Malarkey DE, Ruslander D, Proulx D and Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas Veterinary and Comparative Oncology 2006; 4: 33-40.
49. Bergkvist GT, Argyle DJ, Morrison L, MacIntyre N, Hayes A and Yool DA. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Veterinary and Comparative Oncology 2011; 9: 106-117.
50. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Journal of Pharmacology and Experimental Therapeutics 2001; 296: 235-242.
51. Green JR and Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. American Journal of Clinical Oncology 2002; 25(6 Suppl. 1): S3-S9.
52. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 1998; 13: 581-589.
53. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
54. Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, Shi S and Zhang L. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. American Journal of Pathology 2010; 177: 280-290.
55. Weinstein RS, Roberson PK and Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. The New England Journal of Medicine 2009; 360: 53-62.
56. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J and Bennett CL. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet Oncology 2008; 9: 1166-1172.
57. Yamashita J and McCauley LK. Antiresorptives and osteonecrosis of the jaw. The Journal of Evidence-Based Dental Practice 2012; 12(Suppl. 3): 233-247.